MedTrace Logo

Liposomal Bupivacaine in Bariatric Surgery

NCT03373591 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2019-11-04

Study results available
· View outcomes & findings →

Summary

The aim of this study is to perform a randomized controlled trial for patients undergoing bariatric surgery, comparing the need for opiates with and without administration of a transversus abdominis plane (TAP) block using the long acting local anesthetic, liposomal bupivacaine (Exparel®). From this study, the investigators will assess whether use of long acting local anesthetic can reduce the need for opiates in the bariatric population.

Conditions

  • Bariatric Surgery Analgesia

Interventions

DRUG

Liposomal Bupivacaine TAP block

Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.

DRUG

Bupivacaine TAP block

Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2018-06-30
Completion
2018-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03373591 on ClinicalTrials.gov